Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label use for other seizure types and anxiety disorders.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is typically 5 mg twice daily. The dose can be increased by 5-10 mg/day every week. The usual maintenance dose is 10-20 mg twice daily. Maximum recommended dose is 20 mg twice daily.
* **Other Indications:** Dosing is highly variable and should be individualized based on the specific indication and patient response.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 years and older):**
* Initial dose: 2.5 mg twice daily.
* Maintenance dose: Titrated to effective dose, typically 5 mg twice daily.
* Maximum recommended dose: 10 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted due to potential for increased CNS effects.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, lethargy, aggression, irritability, and difficulty with coordination. Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, and withdrawal symptoms upon discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedatives):** Additive CNS depressant effects, increasing risk of sedation, respiratory depression, and death.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam concentrations.
* **Valproic Acid:** Co-administration has been associated with increased valproic acid levels and somnolence.
## Monitoring
* Monitor for signs of somnolence, sedation, and respiratory depression, especially when initiating therapy or increasing the dose.
* Assess for behavioral changes, including aggression, irritability, and suicidal ideation.
* Monitor for signs of withdrawal if discontinuing the medication.
* Consider monitoring plasma concentrations in cases of suspected non-adherence, lack of efficacy, or toxicity.
## Clinical Pearls
* Clobazam has a longer half-life compared to many other benzodiazepines, which may allow for less frequent dosing.
* Withdrawal symptoms can occur even with gradual tapering. Taper slowly over weeks or months.
* Due to the risk of serious skin reactions, patients should be advised to seek immediate medical attention if they develop a rash.
* Clobazam is an FDA-approved adjunctive therapy for LGS in specific pediatric populations. Off-label use requires careful consideration of risks and benefits.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace clinical judgment. Always consult the official prescribing information and relevant literature for the most up-to-date and comprehensive guidance.*
